Fixation effect of surepath preservative fluids using epidermal growth factor receptor mutation-specific antibodies for immunocytochemistry

Cancer Cytopathology

Volumn 122, Issue 2, 2014, Pages 145-152

  Kawahara, Akihiko ^a   Taira, Tomoki ^a   Abe, Hideyuki ^a   Watari, Kosuke ^b   Murakami, Yuichi ^b   Fukumitsu, Chihiro ^a   Takase, Yorihiko ^a   Yamaguchi, Tomohiko ^a   Azuma, Koichi ^c   Akiba, Jun ^c   Ono, Mayumi ^b   Kage, Masayoshi ^a  

^a KURUME UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell block; Epidermal growth factor receptor mutation specific antibodies; Immunocytochemistry; Liquidbased cytology; Lung cancer

Indexed keywords

ALCOHOL; CELL NUCLEUS ANTIGEN; CYTORICH BLUE; CYTORICH RED; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FORMALDEHYDE; PRESERVATIVE; UNCLASSIFIED DRUG; ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; DNA DETERMINATION; EGFR GENE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; PRESERVATION; PRIORITY JOURNAL; STORAGE; ADENOCARCINOMA; CELL BLOCK; EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-SPECIFIC ANTIBODIES; GENETICS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LIQUID-BASED CYTOLOGY; LUNG TUMOR; METHODOLOGY; MUTATION; TISSUE FIXATION; TUMOR CELL LINE;

CELL BLOCK; EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-SPECIFIC ANTIBODIES; IMMUNOCYTOCHEMISTRY; LIQUID-BASED CYTOLOGY; LUNG CANCER;

ADENOCARCINOMA; ANTIBODIES; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE FIXATION;

EID: 84897957933     PISSN: 1934662X     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.21355     Document Type: Article

References (22)

1. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
2. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013; 15:415-453.
3. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26:1472-1478.
4. Sholl LM, Xiao Y, Joshi V, et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol. 2010;133:922-934.
5. Kawahara A, Yamamoto C, Nakashima K, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res. 2010;16:3163-3170.
6. Kawahara A, Azuma K, Sumi A, et al. Identification of non-smallcell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer. 2011;74:35-40.
7. Azuma K, Okamoto I, Kawahara A, et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol. 2012;7:122-127.
8. Kawahara A, Taira T, Azuma K, et al. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer. 2012;78:39-44.
9. Fischer AH, Clayton AC, Bentz JS, et al. Performance differences between conventional smears and liquid-based preparations of thyroid fine-needle aspiration samples: analysis of 47,076 responses in the College of American Pathologists Interlaboratory Comparison Program in Non-Gynecologic Cytology. Arch Pathol Lab Med. 2013;137:26-31.
10. Taira T, Kawahara A, Yamaguchi T, et al. Morphometric image analysis of pancreatic disease by ThinPrep liquid-based cytology. Diagn Cytopathol. 2012;40:970-975.
11. Aikawa E, Kawahara A, Hattori S, et al. Comparison of the expression levels of napsin A, thyroid transcription factor-1, and p63 in nonsmall cell lung cancer using cytocentrifuged bronchial brushings. Cancer Cytopathol. 2011;119:335-345.
12. Kirbis IS, Maxwell P, Fležar MS, Miller K, Ibrahim M. External quality control for immunocytochemistry on cytology samples: a review of UK NEQAS ICC (cytology module) results. Cytopathology. 2011;22:230-237.
13. Didelot A, Le Corre D, Luscan A, et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp Mol Pathol. 2012;92:275-280.
14. Shieh JM, Wei TT, Tang YA, et al. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. PLoS One. 2012;7:e30240.
15. Schmitt F, Cochand-Priollet B, Toetsch M, Davidson B, Bondi A, Vielh P. Immunocytochemistry in Europe: results of the European Federation of Cytology Societies (EFCS) inquiry. Cytopathology. 2011;22:238-242.
16. Gong Y, Sun X, Michael CW, Attal S, Williamson BA, Bedrossian CW. Immunocytochemistry of serous effusion specimens: a comparison of ThinPrep vs cell block. Diagn Cytopathol. 2003;28:1-5.
17. Hudock JA, Hanau CA, Christen R, Bibbo M. Expression of estrogen and progesterone receptors in cytologic specimens using various fixatives. Diagn Cytopathol. 1996;15:78-83.
18. Canfell K, Gray W, Snijders P, et al. Factors predicting successful DNA recovery from archival cervical smear samples. Cytopathology. 2004;15:276-282.
19. Zhao FH, Hu SY, Bian JJ, et al. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China. Cancer Cytopathol. 2011;119:387-394.
20. McLeer-Florin A, Moro-Sibilot D, Melis A, et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol. 2012;7:348-354.
21. Kawahara A, Akiba J, Abe H, et al. EML4-ALK-positive lung adenocarcinoma with signet-ring cells. Diagn Cytopathol. 2012; doi: 10.1002/dc.22936.
22. Dejmek A, Zendehrokh N, Tomaszewska M, Edsjö A. Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality. Cancer Cytopathol. 2013;121:344-353.